In Vitro Diagnostics Market: By Product Type (Reagents and Kits, Instruments, Software, Services), By Technology Analysis (Immunoassay, Hematology, Microbiology, Urinalysis, Coagulation and Hemostasis, Others), By Application Analysis (Diabetes, Cardiology, Oncology, Nephrology, HIV/AIDS, Drug Testing, Autoimmune Diseases, Others), By End-user (Hospitals, Laboratories, Academic Institutes, Others) and Geography  

In Vitro Diagnostics Market size was valued at 88.13 billion in 2022 and is poised to grow at a CAGR of 3.2% from 2023 to 2029. In vitro diagnostics are used to detect infectious diseases, and also used to monitor the health status of a person and therapeutic procedures by examining the specimens like blood, tissue, urine, stools and other bodily fluids. Various technologies are incorporated in In Vitro Diagnostics Market as microarray techniques, mass spectrometry, polymerase chain reaction and sequencing technology are used for testing the sample preparation. Growing geriatric population, increased awareness of regular body profiling, particularly among health-conscious people, increasing need for rapid and error-free disease diagnosis, and technological advancements in in vitro diagnostic techniques are some of the key factors driving the global in vitro diagnostics market forward.

In Vitro Diagnostics Market Key Developments:

• In 2015 April, Abbott and Sekisui entered into an agreement for providing solutions of coagulation testing for laboratories across the world.
• In 2014 December, Roche expanded its CE-IVD for testing of human organ and tissue for next-gen blood screening assays. cobas MPX and Cobas WNV assays can be used to test tissue and human organ, therefore expanding the range of approved uses for the cobas 6800/8800 systems and assays. In vitro diagnostics are focusing on acquisitions, exclusive agreements and strategic collaborations in order to expand their business.